Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR8028 Phase 3 Study in Dry Eye Disease
NCT05841043Phase 3Completed
- Sponsor
- Hengrui
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine ophthalmic solution in dry eye disease (DED) (2 arms), sponsored by Hengrui. Primary endpoints: Change in total corneal fluorescein staining score at Day 29 and Change in eye dryness score at Day 29. Started Mar 2021; status: completed.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05841043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841043.